Nuvalent Stock Today
| NUVL Stock | USD 84.22 0.42 0.50% |
Performance0 of 100
| Odds Of DistressLess than 44
|
Nuvalent is selling for 84.22 as of the 22nd of December 2024. This is a 0.5 percent decrease since the beginning of the trading day. The stock's lowest day price was 82.81. Nuvalent has about a 44 percent probability of financial distress in the next few years of operation and has generated negative returns over the last 90 days. The performance scores are derived for the period starting the 23rd of October 2024 and ending today, the 22nd of December 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 29th of July 2021 | Category Healthcare | Classification Health Care |
Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts. Nuvalent Inc operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 65.62 M outstanding shares of which 5.08 M shares are now shorted by private and institutional investors with about 11.94 trading days to cover. More on Nuvalent
Moving together with Nuvalent Stock
Moving against Nuvalent Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Nuvalent Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| President CEO | James Porter | |||||||||||||||||||||||||||||||||||
| Thematic Idea | IT (View all Themes) | |||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, NASDAQ Composite, NASDAQ Health Care, IT, Health Care, Biotechnology, Biotechnology, Healthcare, Computing (View all Sectors) | |||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||
Debt LevelsNuvalent can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Nuvalent's financial leverage. It provides some insight into what part of Nuvalent's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||
Nuvalent (NUVL) is traded on NASDAQ Exchange in USA. It is located in One Broadway, Cambridge, MA, United States, 02142 and employs 127 people. Nuvalent is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a current market capitalization of 5.98 B. Nuvalent conducts business under Biotechnology sector and is part of Health Care industry. The entity has 65.62 M outstanding shares of which 5.08 M shares are now shorted by private and institutional investors with about 11.94 trading days to cover.
Nuvalent currently holds about 256.96 M in cash with (99.74 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.31.
Check Nuvalent Probability Of Bankruptcy
Ownership AllocationThe majority of Nuvalent outstanding shares are owned by institutional investors. These third-party entities are usually referred to as non-private investors looking to shop for positions in Nuvalent to benefit from reduced commissions. Consequently, institutional holders are subject to a different set of regulations than regular investors in Nuvalent. Please pay attention to any change in the institutional holdings of Nuvalent as this could imply that something significant has changed or is about to change at the company.
Check Nuvalent Ownership Details
Nuvalent Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| T. Rowe Price Associates, Inc. | 2024-09-30 | 1.1 M | |
| Wellington Management Company Llp | 2024-09-30 | 1 M | |
| Commodore Capital Lp | 2024-09-30 | 940 K | |
| Driehaus Capital Management Llc | 2024-09-30 | 864 K | |
| Geode Capital Management, Llc | 2024-09-30 | 855.6 K | |
| Fred Alger Management, Llc | 2024-09-30 | 627.7 K | |
| Pictet Asset Manangement Sa | 2024-09-30 | 621.1 K | |
| Morgan Stanley - Brokerage Accounts | 2024-09-30 | 471.7 K | |
| Rock Springs Capital Management Lp | 2024-09-30 | 430 K | |
| Deerfield Management Co | 2024-09-30 | 20 M | |
| Fmr Inc | 2024-09-30 | 9.7 M |
Nuvalent Historical Income Statement
Nuvalent Stock Against Markets
Nuvalent Corporate Management
| Darlene Noci | Chief Officer | Profile | |
| Perrin BS | Senior Strategy | Profile | |
| Prof Shair | Head Founder | Profile | |
| John Soglia | Senior Development | Profile | |
| Christopher MD | Chief Officer | Profile | |
| Deborah JD | Chief Secretary | Profile |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Nuvalent. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. For more information on how to buy Nuvalent Stock please use our How to buy in Nuvalent Stock guide.You can also try the Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Nuvalent. If investors know Nuvalent will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Nuvalent listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.49) | Return On Assets (0.19) | Return On Equity (0.30) |
The market value of Nuvalent is measured differently than its book value, which is the value of Nuvalent that is recorded on the company's balance sheet. Investors also form their own opinion of Nuvalent's value that differs from its market value or its book value, called intrinsic value, which is Nuvalent's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Nuvalent's market value can be influenced by many factors that don't directly affect Nuvalent's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Nuvalent's value and its price as these two are different measures arrived at by different means. Investors typically determine if Nuvalent is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Nuvalent's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.